Findings
CASTRATION-SENSITIVE PROSTATE CANCER, SECONDARY
In this secondary analysis of a randomized phase 3 clinical trial with 1313 patients with metastatic castration-sensitive prostate cancer, there was no statistically significant difference in overall survival and progression-free survival between Black and White patients.